United States · Sponsor data

Does Eli Lilly and Company sponsor H-1B visas?

USCIS records show 791 approved H-1B petitions for Eli Lilly and Company (Indianapolis, IN) in fiscal years 2023 to 2026, ranking #171 among the employers listed on NorthAmericans.com. About 98.3% of its decided petitions in that period were approved. Historical approvals show past sponsorship activity; ask the employer whether a current role offers sponsorship.

On this page
  1. Eli Lilly and Company: initial versus continuing approvals
  2. What Eli Lilly and Company's H-1B records tell you
  3. Compare other H-1B sponsors
  4. Occupation and labor-certification evidence for this reported name
  5. Frequently asked questions
  6. Official sources
Key facts
Total H-1B approvals
791 (fiscal years 2023 to 2026)
Initial approvals, FY2026 (partial)
97
Continuing approvals, FY2026 (partial)
129
Approval rate (decided petitions)
98.3%
Petition location on file
Indianapolis, IN
Industry (NAICS)
Manufacturing

H-1B petitions by fiscal year

  • Initial approvals
  • Continuing approvals
Fiscal yearTotal approvalsInitialContinuingInitial denialsContinuing denials
FY2023
Legacy export
112
842820
FY2024
194
1108400
FY2025
259
9116803
FY2026
Partial year
226
9712945

Source: USCIS H-1B Employer Data Hub (FY2023 to FY2026). Partial coverage: FY2026: October 2025 through June 2026. FY2023 uses a legacy export and is excluded from the comparable-year analysis. Counts are petitions decided in each federal fiscal year (October 1 to September 30), grouped by the employer name USCIS reports. "Initial" includes new employment and new concurrent employment; "continuing" includes extensions, changes of employer, amendments and changes with the same employer. Companies that file under several legal names can appear more than once.

Eli Lilly and Company: initial versus continuing approvals

In FY2025, Eli Lilly and Company recorded 91 initial approvals and 168 continuing approvals in the USCIS employer data. Initial petitions made up 35.1% of approvals. Its initial-approval rank was #123 among 1,000 listed employers with FY2025 records. This is a different ranking from the multi-year total shown above.

From FY2024 to FY2025, initial approvals moved from 110 to 91 (-17.3%); continuing approvals moved from 84 to 168 (+100%). A percentage change from a zero baseline is not comparable.

Complete fiscal year Initial approvals Continuing approvals Initial share
FY2024 110 84 56.7%
FY2025 91 168 35.1%

Initial petitions include new employment and new concurrent employment; they are not all first-time hires or cap-subject cases. Continuing petitions cover continuation, changes of employer, amendments and changes with the same employer. These groups follow USCIS Table 2. A higher initial share describes the mix of approved filings, not the probability of getting a job or visa. Compare the initial-approval leaders and complete-year trends.

What Eli Lilly and Company's H-1B records tell you

The table separates initial petitions from continuing petitions. Initial approvals include new employment and new concurrent employment; continuing approvals include extensions, amendments and changes of employer. These are petition decisions, not a count of unique workers or open jobs.

Partial coverage: FY2026: October 2025 through June 2026. Use complete fiscal years for year-over-year trends. The approval rate describes decided petitions across the years shown; it does not predict the outcome of your application. Read the H-1B visa guide to understand the route and the employer sponsorship guide for the employer's steps.

Compare other H-1B sponsors

Browse H-1B sponsors in Indiana to compare employers based in the same state. The H-1B sponsor company list ranks employers using the same USCIS dataset. Before applying for a role, ask whether the employer will sponsor a new petition or a change of employer, and whether the position is eligible. Past approvals do not guarantee sponsorship for a particular job.

Occupation and labor-certification evidence for this reported name

The following DOL records match the employer name and reported state used on this page. They are labor-certification records and are not added to the USCIS petition approvals above. Name/state matching does not roll up affiliated filing entities.

Evidence type Covered period Certified cases Leading reported occupation Median lower wage offer, USD
H-1B labor condition applications FY2024 (complete) 236 Statisticians USD 120,547.5 / year
H-1B labor condition applications FY2025 (complete) 511 Statisticians USD 132,000 / year
H-1B labor condition applications FY2026 through Q3 306 Statisticians USD 141,690 / year
PERM labor certifications FY2025 (complete) 26 Statisticians USD 114,472 / year
PERM labor certifications FY2026 through Q3 23 Manufacturing Engineers USD 125,194 / year

Medians require at least five comparable wage observations. These are offered wages and historical certifications, not actual pay, current vacancies or actual hires. See the full source methodology and employer filing comparison.

Frequently asked questions

Does Eli Lilly and Company sponsor H-1B visas for new hires?

USCIS approved 97 initial H-1B petitions for Eli Lilly and Company in fiscal year 2026 (partial). Initial approvals cover new employment and new concurrent employment. They show historical filing activity, not a promise of sponsorship for a current vacancy.

What is the difference between initial and continuing approvals?

Initial approvals are for new employment or new concurrent employment. Continuing approvals include extensions, amendments and changes of employer.

Does H-1B sponsorship data guarantee a job offer will include sponsorship?

No. Past filings show a company has sponsored workers, not that every role is eligible. Ask the employer directly and confirm the role meets H-1B specialty occupation rules.

Official sources

  1. USCIS: H-1B Employer Data Hubuscis.gov
  2. USCIS: H-1B Specialty Occupationsuscis.gov

General information, not legal advice. NorthAmericans.com is independent and not affiliated with any government.